| scholarly article | Q13442814 |
| P50 | author | Guillermo J Pons-Estel | Q60162040 |
| Howard Belmont | Q67569105 | ||
| Angela Tincani | Q73304219 | ||
| Iana Nascimento | Q88399619 | ||
| Michelle Petri | Q88399621 | ||
| Maria G Tektonidou | Q57034988 | ||
| P2093 | author name string | Tatsuya Atsumi | |
| Jason S Knight | |||
| Medha Barbhaiya | |||
| Paul R Fortin | |||
| Renata Rosa | |||
| Vittorio Pengo | |||
| Maria Efthymiou | |||
| D Ware Branch | |||
| Ozan Unlu | |||
| Doruk Erkan | |||
| Rohan Willis | |||
| Alessandra Banzato | |||
| Danieli Andrade | |||
| Maria Gerosa | |||
| Esther Rodriguez | |||
| Amaia Ugarte | |||
| Lanlan Ji | |||
| Stephane Zuily | |||
| Guilherme Ramires de Jesus | |||
| AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Investigators | |||
| P2860 | cites work | Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus | Q85206714 |
| Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 | ||
| AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update | Q27007774 | ||
| The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus | Q28072610 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support | Q29547407 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients | Q33375598 | ||
| Non-criteria manifestations of antiphospholipid syndrome | Q33388991 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | Q33412915 | ||
| Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 | ||
| Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort | Q33871715 | ||
| Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant | Q36303250 | ||
| Effect of alcohol consumption and smoking on disease damage in systemic lupus erythematosus: data from the Korean Lupus Network (KORNET) registry | Q36365077 | ||
| Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. | Q38113521 | ||
| The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 | ||
| The antiphospholipid syndrome in patients with systemic lupus erythematosus | Q38806198 | ||
| IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis | Q38856073 | ||
| Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome | Q39608521 | ||
| Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012 | Q40513776 | ||
| Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. | Q41939439 | ||
| Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus | Q41977234 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. | Q43786418 | ||
| Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients | Q44830352 | ||
| Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. | Q47680027 | ||
| Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings | Q48371040 | ||
| The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. | Q48854142 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| P433 | issue | 1 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| antiphospholipid syndrome | Q582207 | ||
| P304 | page(s) | 134-141 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Arthritis Care and Research | Q15754720 |
| P1476 | title | The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository | |
| P478 | volume | 71 |
| Q64075728 | Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome | cites work | P2860 |
Search more.